FDA approves Otarmeni as first gene therapy for hearing loss
The US Food and Drug Administration approved Otarmeni in April 2026 as the first gene therapy for hearing loss. Developed by Regeneron Pharmaceuticals, the treatment delivers a functional copy of the OTOF gene to inner-ear hair cells to address a rare form of…
